PT3150256T - Combinação de anticorpo anti-cd20 e inibidor seletivo de quinase pi3 - Google Patents

Combinação de anticorpo anti-cd20 e inibidor seletivo de quinase pi3

Info

Publication number
PT3150256T
PT3150256T PT161850904T PT16185090T PT3150256T PT 3150256 T PT3150256 T PT 3150256T PT 161850904 T PT161850904 T PT 161850904T PT 16185090 T PT16185090 T PT 16185090T PT 3150256 T PT3150256 T PT 3150256T
Authority
PT
Portugal
Prior art keywords
antibody
combination
selective inhibitor
kinase selective
kinase
Prior art date
Application number
PT161850904T
Other languages
English (en)
Original Assignee
Rhizen Pharmaceuticals S A
Laboratoire Frana§Ais Du Fractionnement Et Des Biotechnologies
Tg Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S A, Laboratoire Frana§Ais Du Fractionnement Et Des Biotechnologies, Tg Therapeutics Inc filed Critical Rhizen Pharmaceuticals S A
Publication of PT3150256T publication Critical patent/PT3150256T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT161850904T 2012-11-02 2013-11-01 Combinação de anticorpo anti-cd20 e inibidor seletivo de quinase pi3 PT3150256T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4595CH2012 2012-11-02
US201361771812P 2013-03-02 2013-03-02

Publications (1)

Publication Number Publication Date
PT3150256T true PT3150256T (pt) 2020-08-31

Family

ID=73052261

Family Applications (1)

Application Number Title Priority Date Filing Date
PT161850904T PT3150256T (pt) 2012-11-02 2013-11-01 Combinação de anticorpo anti-cd20 e inibidor seletivo de quinase pi3

Country Status (4)

Country Link
ES (1) ES2813343T3 (pt)
HR (1) HRP20201196T1 (pt)
HU (1) HUE050878T2 (pt)
PT (1) PT3150256T (pt)

Also Published As

Publication number Publication date
HRP20201196T1 (hr) 2020-11-13
HUE050878T2 (hu) 2021-01-28
ES2813343T3 (es) 2021-03-23

Similar Documents

Publication Publication Date Title
IL238564A0 (en) Combination of an antibody against 20cd with a selective pi3 kinase inhibitor
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
IL267681A (en) Selective grp94 inhibitors and their uses
HK1223089A1 (zh) 激酶抑制劑及其用途
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
HK1219421A1 (zh) 激酶抑制劑的組合及其用途
EP2683243A4 (en) PI3 KINASE INHIBITORS AND USES THEREOF
EP2721031A4 (en) BROMODOMA INHIBITORS AND ITS USE
EP2705039A4 (en) BROMODOMAIN INHIBITORS AND USES THEREOF
HK1217949A1 (zh) 雙重選擇性 δ和γ激酶抑制劑
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
EP3076963A4 (en) Combination of aurora kinase inhibitors and anti-cd30 antibodies
PT3150256T (pt) Combinação de anticorpo anti-cd20 e inibidor seletivo de quinase pi3
EP2986627A4 (en) EPH-A RECEPTOR INHIBITORS AND USES THEREOF